Mixidol - General Information:
A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)
Mixidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Mixidol has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Mixidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Mixidol for patients
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL. A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline. In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations. Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
Since the pharmacologic and clinical actions of HALDOL Decanoate 50 and HALDOL Decanoate 100 are attributed to HALDOL (haloperidol) as the active medication, Contraindications, Warnings, and additional information are those of HALDOL, modified only to reflect the prolonged action. HALDOL is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have Parkinsonís disease.
Other Brand Names containing Haloperidol:
ALDO; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Apo-Haloperidol; Bioperidolo; Brotopon; Dozic; Dozix; Einalon S; Eukystol; Galoperidol; Haldol; Haldol Decanoate; Haldol La; Haldol Solutab; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidol Decanoate; Haloperidol Intensol; Haloperidol Lactate; Halopidol; Halopoidol; Halosten; Keselan; Lealgin Compositum; Linton; Mixidol; Novo-Peridol; Pekuces; Peluces; Peridol; Pernox; Pms Haloperidol; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium;
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..